Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role
Authors:
- 2 August 2022
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 367, 56-62
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 27 references indexed in Scilit:
- The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western dietDiabetologia, 2016
- Interpretation of the evidence for the efficacy and safety of statin therapyThe Lancet, 2016
- SAP deficiency mitigated atherosclerotic lesions in ApoE−/− miceAtherosclerosis, 2016
- Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose LoweringJournal of Clinical Medicine Research, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review)Vascular Pharmacology, 2015
- AMPK promotes macrophage fatty acid oxidative metabolism to mitigate inflammation: implications for diabetes and cardiovascular diseaseImmunology & Cell Biology, 2014
- Genistein Suppresses LPS-Induced Inflammatory Response through Inhibiting NF-κB following AMP Kinase Activation in RAW 264.7 MacrophagesPLOS ONE, 2012
- Macrophage α1 AMP-activated Protein Kinase (α1AMPK) Antagonizes Fatty Acid-induced Inflammation through SIRT1Journal of Biological Chemistry, 2010
- Berberine suppresses proinflammatory responses through AMPK activation in macrophagesAmerican Journal of Physiology-Endocrinology and Metabolism, 2009